This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO Co., Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO Co., Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company. References
1) NICE. Edoxaban for preventing stroke and systemic embolism in people with
non-valvular atrial fibrillation. Issued September 2015, TA 355. Available at:
http://www.nice.org.uk/guidance/ta355.
2) NICE. Final appraisal determination: Edoxaban for preventing stroke and systemic
embolism in people with non-valvular atrial fibrillation. Issued 6 August 2015.
Available at:
https://www.nice.org.uk/guidance/gid-tag475/resources/atrial...-
edoxaban-tosylate-id624-final-appraisal-determination-document2.
3) Lip G, et al. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial
fibrillation. J. Comp. Eff. Res. (2015) 4(4), 367-376.
4) Iqbal MB, et al. Recent developments in atrial fibrillation. BMJ. 2005;330(7485)
:238-43.
5) NICE. Support for commissioning anticoagulant therapy. Commissioning guide 49. Issued
14 May 2013. Available at:
http://www.nice.org.uk/guidance/cmg49/resources/non-guidance...
-anticoagulation-therapy-pdf.
6) NICE. Thousands of strokes in people with common heart rhythm disorder are avoidable,
says NICE. Press release issued 18 June 2014.
7) Ball J, et al. Atrial fibrillation: Profile and burden of an evolving epidemic in the
21st century. Int J Cardiol. 2013;167: 1807-24.
8) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task Force
for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
Eur Heart J. 2010;31(19):2369-2429.
9) Krijthe BP, et al. Projections on the number of individuals with atrial fibrillation
in the European Union, from 2000 to 2060. Eur Heart J. 2013;34(35):2746-2751.
10) World Health Organization. The top 10 causes of death. Available at:
http://www.who.int/mediacentre/factsheet... [Last accessed:
September 2015].
11) National Heart, Lung and Blood Institute - What is Atrial Fibrillation. Available at:
http://www.nhlbi.nih.gov/health/dci/Dise.... [Last accessed:
September 2015].
12) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N
Engl J Med. 2013;369(22):2093-2104.
Contact
Lydia Worms (Europe)
Daiichi Sankyo Europe GmbH
Edoxaban Communications & Product PR Europe
+49(89)7808751
EmptyBreak:MARKER
Yasuki Minobe (Global)
Daiichi Sankyo Group
Corporate Communications Department
+81(3)62251126
